Product Description
for Alcohol Dependence (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01613014)
Mechanisms of Action: V3 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Depressive Disorder, Major|Binge Drinking|Alcoholism
Phase 1: Depressive Disorder, Major|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCIG-004 | P2 |
Completed |
Binge Drinking|Alcoholism |
2015-05-01 |
|
| M11-733 | P2 |
Terminated |
Depressive Disorder, Major |
2013-10-01 |
|
| M12-674 | P1 |
Completed |
Depressive Disorder, Major |
2011-09-01 |
|
| M11-731 | P1 |
Completed |
Healthy Volunteers |
2010-02-01 |